0001493152-22-026762.txt : 20220926 0001493152-22-026762.hdr.sgml : 20220926 20220926090014 ACCESSION NUMBER: 0001493152-22-026762 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220926 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220926 DATE AS OF CHANGE: 20220926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 221263675 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm
0001535955 false 0001535955 2022-09-26 2022-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

September 26, 2022

 

 

 

LIPOCINE INC.

 

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357

 

Delaware   99-0370688

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events

 

On September 26, 2022, the Company issued a press release announcing a strategic realignment and forward focus on treating CNS disorders. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No.   Description
     
99.1   Press Release announcing “Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders”
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      LIPOCINE INC.
       
Date: September 26, 2022   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer

 

 

 GRAPHIC 2 form8-k_01.jpg begin 644 form8-k_01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#H?A7XNU[7 M_$]S:ZIJ+W,"632*C(HPP=!G@#L3^=>O5X-\$_\ DX-6HO;%/ M-27&"4'WE)[C&3]10!VMM<0W=M%BCN:X+X0Z\%\':A'>S;8-,D,F]CPD9!8C\"&/XUQ0&J?%?QN1N M>&S3)&>1;PY_(L?U/L. #3U'XI>)_$5Z;/PW9O;JWW5AC\Z9AZDX('X#CUIJ M^&_BK=#SFO=1C+<[3J6S] _%>PZ'X?TSP[8+9Z9;+#&/O-U9SZL>YK3H \%E MU7XF>#SYMZ;R2W7EFG N(R/=QDC\P:[OP=\4=/\ $'K2+4-2A2;5G M;Y@&6W]E_P!KU/Y>_?T >$OI7Q6T;_2%N-3G YPMT+C_ ,<).?RK4\.?&*Y@ MNA9>)[4 !MC7,495T/\ MI_ACZ&O8JY?QAX(TWQ99/YD:0WZK^YNE7Y@>P;U M7V_*@#H[:Y@O+:.YMI4E@E4,DB'(8'N#7DWPX\7:]K7C6XL=1U%Y[989&6-D M4 $, .@]ZO\ PUT?QAX:OI-.U2P(TB0,5?[1&PB<\W_H:T 0^*O'WBBP\5ZK:6NKRQP0W+I&@1#M4'@U@OOC=-UZ,#R*FH \AU[ MQ=KUI\7XM&@U%TT]KVUC, 1<;7$>X9QGG_P#"=_VY!_PB_G_8?LR[ M_+\O'F;FS][GIMKBO$W_ "7J#_L(67_H,5>\T >)_P#%WO\ I[_\@4?\7>_Z M>_\ R!7ME% 'B?\ Q=[_ *>__(%=#XW36&U&(EYTB$"&+ )C8[7\Q3@'YRVS M'0XZ$HT4 >#?!/_D< MKS_L'O\ ^C(Z]YKP;X)_\CE>?]@]_P#T9'7O- !7AGQN_P"1FT__ *\__9VK MW.O#/C=_R,VG_P#7G_[.U &S\9?^19T/_KH?_0!7>>"?^1'T3_KSC_\ 017! M_&7_ )%G0_\ KH?_ $ 5WG@G_D1]$_Z\X_\ T$4 ;U>??%7Q5::7X;N-)CE5 M]0O5\ORU.2D9^\S>F1P/K[4GCGPQXLOKQ;GPYK-VL4WRS6OVHQA/]I3GIZC^ MG PO#_P;F-ZMYXDO4E ;<;>!BQD/^TYQ^GYT /+FPGPLD MMO)"!_MJP/\ )6H ]YHHHH **** "O!OA+_R42Z_Z]YO_0UKWFO!OA+_ ,E$ MNO\ KWF_]#6@ TS_ )+T_P#V$)__ $%J]2\=^$X_%GA^2W4*+Z',EK(>,-_= M)]#T_(]J\MTS_DO3_P#80G_]!:O>: /&?A/XMDTZ]?PKJA:,-(PMO,X,/?%OPB\$R^*=-0JP91=B/@JP^[)_('\#ZUVGP_\7IXKT%6E M91J%MB.Y3U/9Q['^8- 'F?B;_DO4'_80LO\ T&*O9M1\1:-I%PMOJ.IVMK,R M;PDT@4EH/\ L(67_H,5>D>+/AUIWB[58K^[O+J&2. 0 MA8=N" S'/(//S&@#3_X3;PO_ -!_3_\ O^M'_";>%_\ H/Z?_P!_UKC_ /A2 M.B?]!/4/S3_XFC_A2.B?]!/4/S3_ .)H ]&L;^TU.U6ZL;F*X@8D+)$VY3@X M/-6*R?#>@6_AG1(M+MI998HF9@\N-QW$GM]:UJ "BBB@#P;X)_\ (Y7G_8/? M_P!&1U[S7S)X&\5IX/UN;4)+1KH26S0;%?9C+*V5M_P! M&7_P)'_Q- 'K5>&?&[_D9M/_ .O/_P!G:MG_ (7E;?\ 0!E_\"1_\36#\8YQ M=:UI%P%VB73U?;G.,LQQ0!O?&7_D6=#_ .NA_P#0!7>>"?\ D1]$_P"O./\ M]!%<'\9?^19T/_KH?_0!7>>"?^1'T3_KSC_]!% &]1110!E^(M&B\0>'[W2Y M2%%Q&0K'^%ARI_ @&O&?AWXE?P7XDNM#UG,%O-)Y@KWJ MN&\>_#NW\5I]MM&2WU5%P'/W9@.@;^A_R #N 0RAE(((R".]+7@&F^+O%WP\ MF73-2M'DM4X2"Y!P!_TS<=OS'M76P_&_26C!GTF]23NJ,C#\R1_*@#U*N2\> M^,8/"FBOYP'\"_E[#N #1^#7AR4S7/B2Z4[6!A MMBW5B3\[?TS_ +U8OQ"TR\\'^/H]>L05BN)?M,3XX$G\:GZG)^C5[M;6T%G: MQ6UM$D4$2A$C08"@= *HZ_H-CXCTF73K^/=$_*L/O(W9E/8B@"+PUXCL?$^D M1W]DXY $L1/S1/W4_P"/>MBOGV_\/>+/AKJCW^G/+):9_P"/B%=T;KZ2+V_' M\#72:9\<(_*"ZKI#^8!R]K(,'_@+=/S- 'KU5=2U*TTC3YKZ^G6&VA7<[M_( M>I]J\QO?CA9+"?L&CW#RD<>?(JJ/RSG]*Y80^,OBE?QM*#'IZMD,5*6\7KC^ M\?S/T% 'HWA7XD?\)9K9L+319HX45GDN'F!"*.F1CJ3@8S_*N!^$O_)1+K_K MWF_]#6O7O"WA:P\)Z2+*R!9F.Z:9A\TK>I]!Z#M7D/PE_P"2B77_ %[S?^AK M0 :9_P EZ?\ ["$__H+5[S7@VF?\EZ?_ +"$_P#Z"U>\T 1SP175O);SQK)# M*I1T89#*1@@UX%=PWWPJ\?I/"'DT^0DIS_KH">5/^TO'X@'H:^@:YWQKX6A\ M6>'Y;,[5ND_>6TI_A?T/L>A_^M0!Y!J]];ZG\:[&]M)!);SWMBZ,.X*Q5] U M\M^'+::S\>:1;7,;13Q:G"DB-U5A*H(KV/QU\4X/!&MPZ9)I4EV9;9;CS%F" M8RS+C&#_ '?UH ]!HKQ?_AH2U_Z%V;_P*'_Q-'_#0EK_ -"[-_X%#_XF@+'M M%%>+_P##0EK_ -"[-_X%#_XFO989/.@CEQC>H;'ID4 /HHHH S?^$=T3_H#Z M?_X#)_A1_P ([HG_ $!]/_\ 9/\*HP>+(+N+SK;2]5FB+,HDCMLJ<$@X.?4 M&MR"7SX(Y?+>/>H;9(,,N>Q'8TVFMR8SC+9E'_A'=$_Z ^G_ /@,G^%37&DZ M;=E#L->@FEL9&/DR&.1'7:RD>WH>QJ;3=4M] M5CGDMM^V"=[=]PQ\R'!Q[4-- IQ=K/=:A#)D<8<$C!_ T0:C!<:C=V*; MO.M0ADR.,."1@_@:+,?,BW14%[>0:?8SWERX2&!#([>@ S4&DZM:ZUIZ7MH7 M\MF92KKM964X((['(HL[7#F5^7J7J*S=9UZQT&*WEOW9(YYA"K! _"LKEVT*R!/\ =CVC\AQ7022)%&TDCJB*"S,QP !U)-<^/&5BR^>M MCJ9L>OVT6C>3M_O9^]M]\8H2;V"4XQW9?T[PYHND-OT_2[2W?^^D0#?]]=:T MZ9%+'/"DL3J\;J&5E.0P/((JOINHV^JV?VJV+&/S'C^88.58J?U!I6'=;%NB MLR'7M/FUZXT592M] JNR,N P(!^4]\ C/UJ:+5+:76)]+4O]I@B65P5XVL2! MS^%.S$IQ?7R+M8EYX/\ #E_(9+G1+%W)R7$(4GZD8S5S5-8M-(BC:Y9VDF;9 M##$A>25O15')_D*JV/B2UO+Q+.:UO+&YD!,4=Y#L\S'7:I%;>"O#-I*)8=#L0XZ%H@V/IG-;JJ%4*H 4# ' %+4-Y=1V-E/=S9\J"- MI7P,G:HR?Y4BF[:DU5+?2M.LYC-;6%K!*007BA56(/N!0^HP1Z0VIMN%NL!N M#QSLV[NGKBIK>=+JUBN(\[)4#KGK@C(HL*ZV(5TK3EN_M:V%J+G<6\X0KOR> MIW8SFK=8*>*K>9YA;Z;J=PL,KPL\5ON7,[)5VL MOU%-IK<49QELR:BLJ_\ $.GZ;J]GIES(RW%W]S"Y4]:M%F-23;2 MZ%-])TV2[^UOI]HUR&#><85+Y'0[L9R,"DO-'TS4)1+>Z;9W,@7:'F@5R!UQ MDCIR?SIUEJ-O?S7D4);=:3>1+D8^;:&X_!A3KZ\^PVXE^S7%Q\P79;Q[V^N/ M2BW0.96N4_\ A&- _P"@'IG_ ("1_P"%'_",:!_T ],_\!(_\*KV'BB#4I_* M@T[4L"8PN[6^%1@<$,<\8K2U#4;?3(8I;@MMEF2!=HS\SL%'ZFBSV$IQ:NGH M5?\ A&- _P"@'IG_ ("1_P"%:@ 4 < "JNH:C;Z9#%+<%MLLR0+M&?F=@ MH_4U;I#NKV"BBB@9Y7H6IVD&DI%)XX;3G667-J(XCY?[QNY4GGK^->G6DT=S M9PSPS":.1%991T<$<'CUI_E1_P#/-/RIX P!@5Q^M:7P^N$N]&U"YC#!)=3N)%##! M+9&1V-=8 , 8I .@ H<[IBA1Y6FGL<:-/O;[QMKOV/5[C3]D=MN$4:/ORK M8SN!Z<]/6K'AFVN+3Q3X@AN;V2]E"6I,TB*I/ROQA0!75X&QS235K,N47S0S6TEK.]7:\MC;W<=E#%/&> M@<,W*GNIX(/H:[C SG%)@9)P,GO5<^EC/V.J:?6_Y_YG,:U,FD^++'6+U&_L M\6DELTX4L('+*0S8Z @8S^=8]QKTC^(M-6R\0+J=O/?*KQ):QF.%&R0/, ^] MQ@")ISXDO&A&FLY@\B':5\O.W.W.,<>M=?HW_("T_P#Z]H__ $$5 M>P,8QQ13BV- MY;RZ3#=)>K<0"+<;G@!P!RQQP.A-63%&3DQJ3]*< , #TIRDF*E3<.OY_Y MGFXTS7_$=IJ>H0V>G^5JQ5K>6>=TDAC0_NB $..F[KSFNT\.:JVKZ)#<3+LN MDS#_J<3I7B+1]'UGQ%!J.HP6TKZB7 M5)&P2/+09_0UV-K=07MK']=-@# MH*" >HHYO>N'L_W?(<)XBTG4K.#3Y;K7[J]C&I6H\F2&)03YJ\Y50:[N@@'J 1**'*Z"%-1;:ZA1114FA__]D! end EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

 

 

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

 

Company to apply its proprietary Lip’ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders

 

Initial focus on oral delivery of neuroactive steroids; important near-term clinical milestone for lead candidate LPCN 1154 for postpartum depression (PPD)

 

Company to explore strategic partnerships and other opportunities for non-core assets

 

SALT LAKE CITY, September 26, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules, announced today its plans to focus on treating CNS disorders.

 

“We are excited to announce a new strategic direction for Lipocine, which involves applying our validated Lip’ral technology to develop new treatments for CNS disorders,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc. “Our initial focus is on endogenous neuroactive steroids which have broad applicability in treating various CNS conditions and where we can leverage our platform to develop highly differentiated oral therapeutics.”

 

“The changes we are implementing allow us to focus on a select number of candidates in active development and to manage our resources efficiently,” continued Dr. Patel. “We continue to believe in the value of our non-core candidates and have determined that the optimal way to advance these assets will be through partnership. We believe that this strategy will allow us to diversify risk and can create opportunities for non-dilutive financing.”

 

New Strategic Direction Focused on CNS

 

Lipocine’s priority is to advance its pipeline of endogenous neuroactive steroids (NAS). NAS have been shown to impact central nervous system function largely through allosteric modulation of the GABAA receptor. As a novel drug class, NAS have received considerable attention because of their potential to treat various neuropsychiatric conditions including depression, movement disorders, epilepsy, anxiety, and neurodegenerative diseases.

 

Lipocine believes that its technology can be applied to enable effective oral delivery of endogenous modulators of the GABAA receptor, which historically have been challenging to deliver orally due to poor aqueous solubility. The CNS development portfolio includes LPCN 1154, a fast-acting oral antidepressant for postpartum depression (PPD) with potential for outpatient use; LPCN 2101, with a novel mechanism of action, for women with epilepsy; and additional undisclosed CNS-focused candidates.

 

 

 

 

Lipocine’s most advanced NAS candidate is LPCN 1154, a non-invasive, oral formulation of the neurosteroid brexanolone which the company is developing for the treatment of PPD. Lipocine recently announced that the U.S. Food and Drug Administration (“FDA”) has agreed with the Company’s proposal for establishing the efficacy of LPCN 1154 through a pivotal pharmacokinetic (“PK”) bridge to an approved IV infusion brexanolone via a 505(b)(2) NDA filing. The pilot PK bridge study (a prelude to a pivotal study required for NDA filing) is ongoing with results expected in the first quarter of 2023.

 

Planned Monetization of Non-Core Assets

 

Lipocine has developed a portfolio of clinical stage candidates including LPCN 1144 for treatment of non-cirrhotic NASH, LPCN 1148 for decompensated liver cirrhosis, LPCN 1107 for prevention of pre-term birth, and LPCN 1111, a once-a-day therapy for TRT. The Company intends to advance these programs further through partnerships, a strategy that is designed to diversify risk and potentially create opportunities for non-dilutive financing. As a result, no further significant investment is expected for these programs. The Company plans to complete the ongoing Phase 2 proof-of-concept study for LPCN 1148 in liver cirrhosis and continues to explore ex-U.S. commercialization of FDA approved TLANDO through partnering.

 

Lipocine had $37.4 million of unrestricted cash, cash equivalents and marketable investment securities, as of June 30, 2022. The Company believes that this cash will be sufficient to support operations and capital expenditure until at least September 30, 2023.

 

About Lipocine

 

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop products for CNS disorders. Lipocine has candidates in development and candidates for which we are exploring partnering which target large addressable markets with significant unmet medical needs. Our candidates represent enablement of patient friendly oral delivery options for favorable benefit to risk profile.

 

Lipocine clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy and LPCN 1148, an oral prodrug of bioidentical testosterone targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering LPCN 1144, our candidate for treatment of non-cirrhotic NASH, LPCN 1148, LPCN 1107, our candidate for prevention of pre-term birth, and LPCN 1111, a once-a-day therapy candidate for testosterone replacement therapy (TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

 

 

 

 

Forward-Looking Statements

 

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products to treat CNS disorders, our ability to monetize non-core product candidates, the application of our Lip’ral platform in developing new treatments for CNS disorders, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates to treat CNS disorders, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

 

For further information:

Krista Fogarty

Phone: (801) 994-7383

kf@lipocine.com

 

Investors:

Hans Vitzthum

Phone: (617) 430-7875

hans@lifesciadvisors.com

 

 

 

 GRAPHIC 4 ex99-1_01.jpg begin 644 ex99-1_01.jpg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end EX-101.SCH 5 lpcn-20220926.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 lpcn-20220926_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 lpcn-20220926_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 26, 2022
Entity File Number 001-36357
Entity Registrant Name LIPOCINE INC.
Entity Central Index Key 0001535955
Entity Tax Identification Number 99-0370688
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 675 Arapeen Drive
Entity Address, Address Line Two Suite 202
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84108
City Area Code (801)
Local Phone Number 994-7383
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol LPCN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001535955 2022-09-26 2022-09-26 iso4217:USD shares iso4217:USD shares 0001535955 false 8-K 2022-09-26 LIPOCINE INC. 001-36357 DE 99-0370688 675 Arapeen Drive Suite 202 Salt Lake City UT 84108 (801) 994-7383 false false false false Common Stock, par value $0.0001 per share LPCN NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lipocine.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm lpcn-20220926.xsd lpcn-20220926_lab.xml lpcn-20220926_pre.xml form8-k_01.jpg http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "lpcn-20220926_lab.xml" ] }, "presentationLink": { "local": [ "lpcn-20220926_pre.xml" ] }, "schema": { "local": [ "lpcn-20220926.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "LPCN", "nsuri": "http://lipocine.com/20220926", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-26to2022-09-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://lipocine.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-26to2022-09-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lipocine.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001493152-22-026762-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-026762-xbrl.zip M4$L#!!0 ( 9(.E78S:^XXP\ %1* * 97@Y.2TQ+FAT;>UOAF]/#MNM@USYO'72%X>]U?E M'YDD_G,V'JG4J?PFY3_1F8ETJMJM?IKBI"*\?>9RZ=1$1^*]XH5G6%;(-!8O M3;Z0.7V/"BM,*H:YDDZG$W%T>B:.M35YK')[LWJ\R>V6NKHA^;K.9$%-X8.1 M<<[,_A+5'9E9)M-EN^6,D%F6+(5V5F2YR7*MG,R7 LJ]E]M/A=G/92(,?8GS M8B)BE>BYP@"GHFD*SYC@?S%)/)

DO:K7'I ML=X*2@. ?E-5Y$9&#A\(*"\W.K;[0L\RDSL)OT^5S+OX?"8BF(2.\#ID4=89 MV <90:)D+"+ @XYA(>)D<'0J=G8>/>2'F;$ND[DK9E@TRY6UVJ3MUOW!X'CS MAUFL W2H\PRAD71?HC[I*X7;3G5F&?:-FZI4^\E5-EIV* -9*.&"!8Z;ADOD&:[-46>'#RLX:'LC 3S,F-0L+UP/#]\Y39\93B% MLT13F4[P-E1'?@/*E2@R5M*W3!*S$,4JG$EA%1 0G*S@, "#K'B7)7,)!A9T M7:5MF .RE58!N\8W2O04@:S&J&19>@.D,B1!H;Q/L#-4EOZ;$N5CFG0$8,92 M;*@ =#AHP2D#K5)Q@X:$+ R;>ZR(4<*18G"0J70^(&1.SV"&"[F2CN"1+2F& M6.@DP;I5(&EPE9Z >*5(85(X8@"=I7^U>:XQ114+NQ"YMA\!7BGS6!&1TZEK M^$ZLDX(/>:Q3B ==W7E/^>[R'3P_Q&!DCU5\.*[BP\N:D@#[;KY*]-<7@]83 MF,K(%@(K,SYMKA M#"/K =)-BV0MPJ'9\5'%#^-#]A5M.8#R>PRFB+*DJB-T*W3*"EBPOHZ M,>Y@+W.. 0V>(E2&?!NS= BBSL'!EQU&4IX]5CA\2.F!7ULEK?K!<&_).=JM M$%^L#S#D"PWZ2<$#L8E9G"? *B7SH4"KO%M<2GH:[A/LV.3VJW8,4PCD45O\ M2$D-[9$V GGBLW> 3% MPK%)M F&BR.@A++=HE(/995C::&YB-D+[U+"*8)I4QWIVFJ0X&(0PK.;-GR) MAIL"HQT1%$1LM>]+2[L[VSL=/SHX,A)#15Q*VQD=G&3 Z/ ,"P/A_>#2B_;9 M=V3L_1 K%7!)&P%-H#+LNELFP35QN6ON! G_UNV*EUHE\1XHW 1G=Z:@:.#W MGG@HNMW0S#PX?OWK:N.QJD(]Y@8*0U#UV?-$1A_%3N\1M@M[T3%V,NP_/WF! M].CD9- _/GY]^O-/&]L;_//9H']4_AS6"/-%)DED9B%+^7_[T%'LIK2K[7]< M%5F'[\LY8,=LWB7V[=-Y0Q69V_H9HN4X_6Q_BAX&S1R575AK[?+ M:V8 H9+-Q!SXZ^*UMG7]NL/XDG9U.I<6\-GQL$8)]06ZP8$X$!YD\NI<4D M/?(834/*"AL6"*@*G*2R?,Z/JT(%30DX[-65!H)\RM":):\R8_K0.^N!(9N8 M,>V8^$P_1EJE.>GQE?:0NKT\[H<\91-Q B1HDBM,Q=!(4X62<'E,W$5-*,S,#=$O>*!.QP4'B.:1SK7$_(^V']T?;=[?W12GQWVD8@GE81RW@/+& MB<&; M=PJ?/*+*0C]T'=8Y);SC=)>0(N 5C%TV6"#5GLI^(-!AHE9+465N$\#AH>\& MKL <5XATGD\-D(%P^%6G&OZ4A\>*8%.EEDJ4[9;GL/X5JVTU>ON))YUA=YF;(WJ(;'78&)[T3X_?E9IHMX(JZ&!^@,2M@40L_O[@2>\A70Q(@E:*%"9( M-0_'J92%"])709%V+A/NR9"^(=U'Y3A+;ABE55&1LZW#?S@=_E>!X/]@V_<] M5ZVRS,FK4C),B=VRS=U@%PFOJ7GSOI+PJL'JA;*5/7R=!Q$-66UT7>UR-IUSX MX' CX D5%=VOKQ,52$N5Q$:>6"RGO1SO#"3,5\"&"#E7MT@V7P$L.4]9SAKC5-,8X?W"N5 +C ")MC"6<\/59T!8JL:: MP8LY HX,"8I:8_"YXUY2,=NFE5WBMVJO62Q@338RU4[)IIH-@B;_O;(8VJF+ MG'5UX)H)RHIFD]L^?$I4UPM#GD4E 0R%Q_-=!MZ4H\M[7*Z 9WG[K[E?Z!27 M:]CE+'-FAM@JK<7I\&4!=HD+Y*WAK)Y17O:X*A?H<(>XKKI\W:J_M)%):Q,1#Q7PLJHH-+\ MO$B1]<"$:/4Z\QHM&Y=DM*WY[FC)8C ))F&;=T,N*$QB/D^#HHN=AZ8$D#^Q M1GQ,J4$'V)TN,S,QJ00LSSI\R2"F>UDS<#A+Q:=U7]_^.W2-94_O"K(=T30\7> M"5WF /3PW;N[NZDO8,%M=3Z&E+WFRN-G"!)6W/M4&+<_#F><^#.FNELX8O\\ M),!$>6>/7O$H30PH88H7.3R-T%3XQH-:A!:HOFYFF /Y:7.P/Y7 MB!:R!N3GUL?VQK5T+C[YNF#906G<+"[O7JQ>\@2EQB3EC4JZ".>KR:J^H%:* M4/.[#I]'N(Q9$@F:YYJ+SW4Z0B)=??&TW6K@[9%05U.8A? M*5(TI4I'29.JW\/P60K%9JZ@<6TNB'UQ'D\7G)[Q+<-+PZ$=?P>!FB)SK18L MK<,@9:^8KCR8J\Z0;QZNL-?"4I&&/@\9S1?>[XG77 ZBVQ"2KQ$6)&/9_9)) M(FR!%.]ZGRBO$7/.Y ^7VF117EHBSA#JUOU" C8+6SK0++(:D]R_SF@MR MJR5;-1>5H@B3$/:-KWRB5,?WO2[XBH(E?&:-5 )$DKRPO*P'"_^=(D,?OJXZIN7&ZY M4JO?$)U&3K]"^%G%G=ITO)E7=N9G\;OPUN$]_:HYR+<:KS90H_0>;N3Q!U>( M7V[?[]JSWNF^:"B@JL?&69'EOQ-#S&N%\Z[+N0W9=HPITI M,R*W]/<\P_KPCA'2!QBO\W&8\@BKHM[$S'MUN9!LNR!T2F&>HZ2,5]!VD7$. M9W*&,FIJ%'@><2M]^27@"&&W;._6 9E,GAL:TE8]XW8+R5DB%SW/#?X75G!E M.>3;Z,Y=(5/KWG"&G=)E4]\I:Z2R>^LK\AOXM9/MUDL#0N66ZROH8(J8M-=N MW7^ZO;,IGCU[V'WRX.F#]97WX,/AQ_$_FQ6+@ZT/=[KSS9%,\?+#=??+TR:/UE1>^-,71PIO&RH*\Q'-BO_:. M.M672X"/]\4[W[_9$R?4+_Y1$?Q*1?#6:G:W^>OSX8.%HC\XM ?:":J07&\P M6_17H?R?B:*_)O4?4$L#!!0 ( 9(.E5=743O61( 'N. + 9F]R M;3@M:RYH=&WM'6M7XKKVNVOY'W*Y]YREZPRO\A!0.0L!%1^(P(R>^>(*;8!J M:6N3"OCK[T[: H7BZY09F'%FUJ!-LK-W]GLG#0=_CP8:>B(650W],)*,)2*( MZ+*AJ'KO,&*S;C07^;NXO7709] /^NKT,-)GS"S$X\/A,#9,Q0RK%T_F\_GX MB/>).)T*H\!^4B*1C-]>7K3D/AG@J*I3AG693 9IJOZP'#YOG73M6)KJZ\J? M>).DX@N@H569#ICMG(T[C;ZN++!KQNG*O*XJ-=)2DP&C97V3'&>@ MD-P>-2^FW5EP_VG7.+.P3KN&-< ,>,@A9:()*2IE9X!$*9%]@.#W6,]X>A5. M+II*>G 6F..GE#=W,)VLN$+FEMN;$QI@A"1Y'2W270HV&X=6KZ--HSV,S4GG M+J8=T=%M\$%UGT6I;9H:&1"=+1W'^XBQCREO-+78BR/=]KE1 ,\R-$(#9Q(M M/A1EP]:9-0Y>);?1-P!F#43%U^FB4:Y/>FFJ:@\,Z:[5QQ:A=]*=L+T.$"J>O0=.A>/2<&&E%E!:"KQC*&-$V5@C MAY$NB%\!)1,F0VUU %WJ9(B:Q@#K7YP'7P !2^T*05?4)V^]=0E-J)*Q&UF8" .(U0=@.UTC(([E1^X,QTU M;,N;#;H)WA=+1\"WD-W2?WK M;.NJL\B@=@NK.2"8VA8INOI9@#X>,*_)/P6'M@2^H^Q+IW 7073Z\!Q3H[(P M#Q@ 8./BVO*Q0B$P,ZR9YO>OP3R.05!G)JT0W1BH^FO3OKXN\_,& ?;:?:NP ML*"NAL[HHV,>/-MX$(?Q\,G_'ICOM_! !C4B M5J1X0$VLS\*-=O% UQQH46:8+D3W0<=@S!BXSX:JPOH-(:%7+7YNU=JW:VMXJU2NH>EL^+=5/JJA\ M=7E9:[5J5_6-HDMRZ;HIM4YK]9/V5?W+]E8E5HXA*9%)YT.B91']B3EXR3Y\ MJDSQ^*IY"7@*D-SM\YPBGRB+5"D:K1BRS2-?GJ3>R9.L;IK?/6LGYNEM]D)* M7_4!WK\-M6?GBQ1ST?/Y.'NROAND F\7CXZA*>N&.)BC9K7>WMYJ5AM7S?8O MN.IKAG/#MJB-=;:]Q0SH)//B(4JFD&&A9&9'V45&=[,(:O<)N&0BVY;*5!A9 M'WV%BQWDYB&Q= .?\"7OXHA<2&4H>H3 M3.HV$V6WL%GT@2^;]V+2G!=KB$R^ZN3YP>Y,.2]?'>G?DY?=^P^[,Z?D?QA1 M1ZR@P$P#&-=7\'A,(/'4@]R=#[%(L45,&-4AUO:6E/V"..S?RP^N&>&V4]]N MDIY*^>8AX_7^8#MUW2J?/E;3>WDY$T+8'31OI'A1:UR5:_7J]E:M7HY]6J"? MB/-.=81EB @YR[C/MB:L0I@B:A*9E]05I()4,8H@O@(7;NUN%I&;R)BR,1BH ME)_UV-XZ5C6"ZD8,S:OWL4^]>3=0(G#OP:J]E\2GPX3VJ-E*:*H]G9/OR22C MJ6PJL[=4HS>) <%"PW '>"$338/GLCAZDXB(WTVL*-[O[Z9KIIH\*1++AJ9A MDP)"WD_.?LD!L]X_P1.QF"ICS5LO9IC>[LL!4\*IB[E$I/-_A.J0YV0^X9/Y MFBX;%N05XB1,BT&46W9.8Y0-98F'*Y^?7T@W#W7U6@XC$N<'=OB^(".F93QQ M_?"'XF_ $W(HHN$A!/&O:0Y35L0T*52>S>G.RK!>L:@=^42MC4[5"\;UYEL:+9V"0*18CX?3:3V$ME<[@WR _]9ZVQ'8+DFCL%7:5^L MLX<:" FEY+4P@_6)A>YM2Z6**HID/B> POSS4TB%,$^=-4>ST5SXRKI!=N5G MB5ZMV4+5@:D98V+]8K+F-UC(L5@+ C>U27$18!4W-#I<;YQ?*&0Z#J:D*!:A MU/VX4'62#/9N$JFQKM3-MY[3H7FW@,DCQ>Q>9GNK9&$3@BI4L=2G91'2EX7< M*/,*:5(P:?6^]?CU_OOY\[6T0M( =LM6P=_ L%^F_O%J_&6UC:&^ MI 2E['6N;S0%ESMALV Z-3 :VQ[ZP(_$,0?OUFP G5&1 ]75@-2 /"M2S*/ M=+5^\WR3O6V3CP>%[\X\@A&,%+\RW%]"\P+)U2"2&P;,K7U7S>6I5CJ;U5)7 M>O_D]B%L3OIFCQ1SZ61B>?2[:9JTXQ(IMM5,"QBFFEA#9$1DFX$11$877"JA MNV@'5@#Q)?@LR:TJU/<]I2@YW(MRK>(;1^3G'Y&0M"BV?E TG*)Y.Y;S4#.1?G" M@ RPP:E^*04^/;N]H???V\,6#@'M^3EYUIN.[J5RJ5]&ZS=1)X[!'?'M9&?_ MP!+N";)G[-@OT(8N0*SQNY74"YZ#GJJAKWA2H%Q\B(KH A8 ;8@H&M,:P3PZ;:&%', M5-H=BY'N *,#)#A% \,!.;,U:0,<,#I8'WN-74.#V?E '@NK?-^,;M@YH\\- MIS<@G(A)&55?+-5[&G])].()0W@ESGN;,K4[#E-B7<&&Z6EC*.W0E]G3FWRPYH[R3U4/FXB*96(04( ?' M@4O6HNHFTSB:E&:TUW?0>J*[Z43,Z?FIOK^O^GJ.N&$1[O'X6^3BO1L>^EE7 MW>ZR:D&6U)KFR:!TPSY>]'V+&B_':\/5&0B+RC.4O<@H:Q"**CUF^R80D*41VC^H4'.;QF\ $+.<5 M/FZ4O9J]6P\!AH9<_O@L=?P[F_NVJQ_>;U\TTIU>1Y%*AWH@LLTO&>,B1;#< M=ZV,ABE]T4PN(N>R;T*[H-IW]/0EC_U#%BZ9"W?A+"RV %OC0=%6!6BQGRPQ=G#4ULH2>LV03]+Q'CEW8AD]_N MU?_@6?=Y:=R06'_9$2+73#A6(IAEW>;)N/&DUWO#$%CFFR]2Y) M-+S\YVMSAC)?(.43_\ 3HN(5PGF-B]5BF!B2-PX MACW4LXPAZ_/LS>3[F9@BA70AOA?O7#H[)XF,%];/;9LX=URD)JD;7[Z]_>TM ML8V2R.SR$QE.[B=UHE( D* ;,^:@.?D@'[\;V[2,8GWPJ[KLWMZ:X_>\4,4?3 Z1",R Z.C&Z((85,B>@$%[J$-?N>X*NH-SKVE7%K$ M7-I8R/50A;FY1.M #19Y$FE,!!L&=9EOJ^$97%3-D>5W_BN8$NASG$-9:X$ M,KV<: ?O>F9KUE;%'(9-Y.U?\^W#][QYDO,3[Y?T97:!N5_:_*EGK4):7/_R M%YT9UW&^S"LE@$/T0[!)08L#'%6LZRQ%F% MN3?&%KCB@SXK-C]-8M;6)?PPO \ZQ1HC Y2+)9(S9U)1J#-D%50&[PH!H=** 7O"]$;^'"LZX":+%Y'0-S=,W#[,C0+,OCF M$701OGP([A@^99OR@AN#'L)3E^LMI*A46#@:V][B*:A_"LAGNJK&Y^;Y1%_M MJ SE\[&D "S.?7KO&D,?$!L">0U$))-+YG^?K.)'VX#MK3P8 3#*7@0F7@+C M3*>".2ZW:"Q0A7]E3H2.WXZRN[WEK>?ZHKGNRRAN])R>Y2;N@O)7J5PC(](, MUE>I]Q+)^A+SN)D>^]V:.?(=2C''$RD&^;L1>+':_O!67B"4Y;C]F M-R[,-:@0*ENJZ;O>9,TVTW[0S2&A;%ZL%M=?E2L\3%P=3U:_H821\Q5+9)3/ M1Y.Q/AN(PUD0'#<7XV_^TK"4V+]POP0-E9PFF+$UB7LV M+J]X<;EX"1&@)]VW$/':WO@4;"I7R>[YRLC:+$1X_"J*&P%""LF3WYKX3DS$OQ03*>Z5U[L;OMOY ME10@Q4-5YQ>MK2)9\GUKB+-Q M^&BKEEM&>MN1@B]!.XZ*K8V1C&V^23B3T//]OPY!%(B$!L.Y=[I#^ECKHL[8 M>?5<'()V>_"*HJW#( $/VZQO6("^LG%EQ5^[,+ >B=2ZHQ4-_#B/1N M_H>)]_3:?HZ8AWOFG7\I3^%%R5I!.36="96& MF:\4XKA/OU;H!:K>^!I#6$Q+A4KPT?C'LRP;[C7G:C%.X][9X3ZA??0M!IDF M(]I!7%WCTM&G45_K*O5:H.4(M(/*5*H_)7K]T/J4Z#5<\X[@C_@4-1+%R^^7$--[:,KL?%)"^B"7T?Y M65)]I:0:9M$S=(D2/ >RA=][_'2\KH7KK1SE.GN?L+LWP^KM9T0Z$/ M(TUOGGZW2+SYE\&D3-,X.5)/Y+W,<[]T?SS0;??23]\ZXQRC^GXDW1T9 MLTO2U,XJ-:4R/OI')64KDVT^WMX'+2DEMYO7E;^>O?&\VCBE1-]Y*);&HOR<;4 M&.&;2@?_-1[N&=WT9>,DFSEK#P\/G27Y/U!+ P04 " &2#I53V.R@4(5 M W%@ #@ &9OHDH MR1!!$ 01T8E.F.C=(%&":!$2$25J"!/10D;P)$ITT7MG$&74P9@Y\[S7*>\I M'\XY:U_[RWVOZ[[V;Y7_NC=Q@K@ ,.IJZ6@!(! (L",] '$:T "H*"@H*GEWV"O<5V?^S$5L!)BI %T0&!O$# M9$P@,!.(^!/@ P 0.>@?!ORKD3P@Y!245-0TM"2'.D: # 0&DT' Y.00"&DW MG+0/0)C(F:_(J%.P&-E3\GO#9*/2"J@$;E>WL1H/[0G*/?:)IJ:YQ,;.P2ET M55A$5$Q>X;KB#25EC3N:6MIW=71-'I@^-'MD;N'@Z.3LXNKF[NOG'Q 8%!SR M['E,;%S\BX3T5QFO,[/>O,W^4%A47%):]K'\2TUM77W#U\:FOW[\;._H[/K5 M_7MX9'1L?&)R:G%I>65U;1VSL8G=/S@\.C[!G9[]S04"P*!_L_^1BXG$10:! M@"&4?W.!R +_=F""D%^1H6!6-Z*T]V;AEXVB@MU.*ZANHQ:0,]YC?>PS1'-) M4'Y1"/LWVC_(_G=@T?\OLG\'^P^N*8 .#"(E#\P$P %,!"ONF\TXWM#7H]Q= MRI?,7#XA*4&Z;= E4H7E=!QE]BR,A0BD=1\0VG:)0*$ *CB?#)VUU)!PU >V M^=+P^XBR/D'/\T]YN<_T&Y?4\&MC%3]N*2*[^DJ)P'@>H7\$-!9FB+U46>!J MH=_Q-N1XOW?E;G=Y('WC#KU/0""2=??/XK>Z],V[5]6P7QE?=H?P>K@L2^$3 ME?DN_.!G0-5!&WQ? )-WM,Y'B!8!]UH8)AYOK:4%J'&T/N([7"L=BI!R#XDH M..:#3=B!ZU;N)OET[G0%P6/AG,<6BQ&B.)]QL[WB_H+5LN9J0P6A#FKUDXS< M90ZXD1I/9=U/Q8 AJ^FN+S_$XK1-4KN#(:8\@3\Y$;&':]]'2IDZ;IARU[[$ M%#96T2XRH-G:IIX'UG@^NY?ZJSF%FH,\'D_E@!N'47S$VG:L> 4]&19T24,P M(/D[CV[]B*2_J;V4]0*O&?($K^A\O#GO;Y_2_S;NXXW+$> 4"W<<8JER\"#[ MQ"BI0<6@N.80VA[*$+=X(?>CGM:EQ%)<)@4]:SY0P;M6BP&W.8U&7 U2/6TH MV=?S7\U^*BD@,-MQ%]]6M=LV#_,C DP]/"_Q'@YE+52*SDJ&'W([)PC.WY; MH@^!:&GU71M-[+7%7B9+/13F?KR%5.[:E$R,P+>R[>0%[_E-T-;(N%_"]73M M!YKD;]\L ,KI'M$XZV4.5W7[!ZA^0G;E624 =4NH)!V$W"3.!_:^;!@KP70&!UX<+8VKY!]1$#'V-&]%O*&P1#H1 8\1 M@LW%!1"DMV'+6HLXC/DZL@[.D1C\2@0ZJ97P%28_\MBK[)HNV0C7 103XS): MIH-$H#YO,:4 ];C*MH.7:CC,W)'@Z$9_AMKQ>AUA%TIQ9(OHCE16\7@C)5'8 M6/]:*-J4+OU*EUWH,QO]O>7VJ>.Z9L<^2K:J-P"H&F).\#9!!4 M8_R IZ);8MON.V[6U\V7LPLG4$EJ? M" AM0L^IS)$8&3/T(.4+(M ^1P1*6_!1VGCKW;-0(M#%NIUQ_Y\WK*$OAQ]Y M:O';^,6KQ8J3.3C4X=MO4*Y+U/ P*#/]0NE]B%1M9%NR:3_G'?)(F4E,_^XU ML#B?&^C ,1 V9%.H"00IML%/N5'P/Z0O.Y-5/LG>0T0C]Y5LD!,WB<"AH_^N M/& 6&^9%@G]G2 10\(OW%3-;_T5):K!9!,WW4$(3WP5@%KR0=\IT:'AVD$($ MU%G;\*0B2G/1( )5<41 C74N2)AP)YR%@%XF H.: ,(L+\P4:UJ2M?CMY54E MTR/:T7U\G9(HQWGOW%MN**I..#E,9JEGJ[UQ;ZTFH%I_O\_CN)#=\#ACO;2, MD$,G!<5SO9FK7'\A97R?R[LA*I$#>F[@?1;A!^J;UO NP/.@F^R&ZFM"N44G MWF2PY/VL@!:'0-MFKZI(48:WN!Z@BITEYMV9\R/L4Y9-";*/RG'\O=,=S-(D &%*U92 @19LN#06;9-*#>-?1\XTU\\_FG&B)$0C:0SC]J P_/TLXR:N MYYX26).MK^3X1##.)'86L?QV_[OC>3 D>4FAC101>O@B9'YR3K7Q;=^9B<"O.TVDY 2W M'"KD@^\1@?1#(G#,F$=*@/N1% _. 'XI*$+/GT:JH#?S"Z_T_*SPX"$^Q7U_ M5HZ@-TP$)FXC+\@KYES!'1$LN'I]Y2/\M?)+2?))$NA^.A^7M:0SQ\.3@&S0M=N*,J1=H-#29 M[*PFV U2OL6](^B-\!TS?B'!/48YCX1I%KJQT2+*-@/J:V01U/)1.E9IN:&. M?-UHEY_S^S;Y1.!S3!;A&6N(=N(M'K0(V@?'9<,7[V+R M#EE&X/)$8,D5//0)L:V@8MI4W9BP1"$HGG9]]<8-U=&$7WMS48C%]\P2DE/F M3@E7G:&2BCP_<^#9/!+2T;0YL98.XVMT6+KP\ M;^MI-3%;RG.Q'CN(5^8L$(' (Y0Z$8A9]225.P=R3Q")E0=MF2[F<;6L.)." MO35 !%S<)_^SA\(S;+*W?Z4;&RC@A=]1>&._;*^W&M<\!W+%G*2G6P4D5/+ M7&I2)_'=(>7Y!JDSF:SX.FQ/+Y&&,09Y"+)>CT:N: _!M_KA%Y#[%$7$10DAR7/J6QI@O.?IWL ]"54-D M0>;X)O49;W3SYE<$+UZE 6L17C^4/F^JV>I[X@S.1V"07< .B*X@(YJJ2Z!9 M(HCBW=(N6YCJ6[\^W:&5.@-FVM2GE!=RWM,'O*-C/[ M.JYM>3K-.BKELM+X M7WS=D3=U&Z5X<1U0&E?4:E>I\7O=:&K#_)AY.=(#5[R>,-OES,*MK_B9K[4EZ_,.(!]!'^1C MHC#P0C)CV\Z^7F+T!5P%2:K\YDPJ_W?*X!?:C-YLT3B-]CK_0\>%H_?!]0,B1Z4C=-7T!P^RS,__8 M*=:9G?FND#SW Z[YY$MZU.<4*4_WTSKS^,M3>I0NKF4RXGJ67N,]160V-B?I M'A2C;;X2L/B!P?N4A4%F2]IXH>S)S[5#SLFPA\&2O':W13;2DHL6'.#=7_G^ M61C&T1*+'E#J#?[NKDO.*B5OX_JNA>2I8U3,4O%")(%XX4\$; Z0& \U"A*" MT 81^',%3H@>W558F'+!9Y&D_?-STD"@)8TAB&\;ZR@Z\Z#CBX98AI]]:K<6 ME<*"V=/Y,#'LF2%5L/PIM>C &89ZU?!2RZAIDOGC[I'VTR MG+/41<9<0*LQR+,1T IG\]'W4FQ5Q_%O=2'T2;UDDDITM=F@POY\G$1)#78M MS=.72U/5(D>47]'47BSZV@3>'VL A7@\W4AW,[9^ZYFYW&L>[2#>DV3W=Z?E M0]4_H&T)G,SCA)C)ECT14J\A?]PF:?;@-T4".91P-;)Z&V:62+H^_/-B(I*L\^=AV>6%]A',FVO86U>K^W,U-+L=G=(U_M!WT2QJN MRB75._'AM/T,S\"DL.+H\A9-K-R4/2A8..CX5HV>S^3R> MGVW)P7XJR[ZB;?VI*#2$MZ-DV%\O_*'22OU\/?7<[ E=6-=3[VT-?;(V)=;OG%>(VT=?R-[X^#CA!O_=@I<"+RE8&>U$#@'3( 5V206N M;[#9=8OGLH[><9 DOM8ABD+RCL+ Q^_06_=C[R5++Z0]PW&*=_8F^CU@:TAU M.Y:;L_IZUTY#H"$?K$#QJL)BRR+$9HIM?_*M;M.VD].-R\F=_(DJ5DJO3T.R MRC[-NMA4#SYNR+R8%,BUI_EL%2/(\@HC#56X6E@^M9$ZW:/T.(NEDPS&<9JS MB*01_[G.&AX@/F-I.7=[<*8-AE5\\!HLBJ>WUUF TW2O3M_^ B$" 3<+][G- MU 5?P#P%D\L2:.5D6@%_P?%;JDZ/>]8KDTN>A%S46BB^:CB?/)\.QR8P(^PR MEGDFD09[:XE%UR_@>K4-R-TB-<6+H[':C30][KVB:F6T5\'KC!5IU6BQ[^_* MIC?KD>[UX@X'O/ W=JN//EZH%]O//K'\4'-EO/:T;NLEJ].U<+**+[(+TI?Y M,DY:!> 6V1+&4]:/PR7T+DJH,LW(@Z9^1@TL&O3J>H>')=:]"";I/(-MEV/C MD+CUKU_>5,8110X*O@_&).3C"STR ]*=)^EDK@0+(32-?A%NET_@TL?VL>)K M=>CJQE066&#JGP.9<;=?D),.7\WW50S>!GV;FIX+*+HI7:$XC6H&Y4OQUV^] M[?,JC[E?#MR7!KA!>O?GK+4=G&[.3.[GORP.HWM?+HM\S?^NOFC4>%YW^-.: MG.4CBS91"%L"Z\/+YU$:F]+:1==+IF.:6KV@W'^FOY56B7D$_]X/)K[)/%42 <>/, M"^528M75XQUX(MUHU$^Q/"T)1J^/[]Z($//<1GV@+/D4KRMK%X]WNK(/4MD_LQ"!5%BYGSGKII@F MJ77+L^ KGMT$A;KUPTOH7*&]LY?-"1TZO96B*S&H]+K*A @\=U C70%X26(6 MF48:KGQ[2:Y\A^!A^!XS?*_\F%?DF7%>]S.#D<]7I;_5?6=EYV;L5'U<6T>O M-7\O5M2+UC/3,2H@"=_?IKWI6C.AZ^V^@3'];V>Z S )X"Y4VQA8@2#5@# M>7V/K-HWK0@7N\(C!:_4'90=24LX5D,NE;I1I*?I+,<.OW?*NO[A1DK6>ZO=ZKR7<>FFMK0YX&'96>D@1G0![_<0&0IB"W*NYUT'T7 M78/,.\UAB"NUTEZLX$'HW?:G#7CO^)R;M@R]+@0]URC/[=RRL(56,>]JC4@Z MT#%;&RQITDFK2:2E38P_ L# XU1 &1#Q;7HB(0P7S?5N4LJ)VOW>;_Z/\&O8&,#,+"IG M*8EN'>:[85\N*H^?5I)B4UC[&.R2[S;4)I=C/5OT&Z;!+#U5%!E!&B17"X8< M1VJ1K(:(\C9/B$6;W&V)8A=U99$Y6;4VIW4"F4=-:[]W'SLEMU_A.SUP<;#O MO$DVULI-XB3.(K48N M2U6"Z^ AP!@Z7V!BD*LR>RJJ9.WF4X2^/:6NOA'FJJQHZ= M MUD@:A)\'4GS8:]]N/TD^"D#7 M7S_QGM2 87.C?BB*A7Y<>(;Q^$H*@4Y4^E/9T%'?#0>X0[G;44;@)#Q3ZP_NB$\S!E24+A"5JMZ3WZI!O%;-'A M$,,E")6&-G=0*BUD']*X?Q"++,]G:+U?%">FW\QGF?RIA1G954GJRO&,^3-0 MI:[8PZ0QW8W"Z,8A?Z.%%Z6W!-&N6MG]=OM7ILQZ^F>V^V4Z*_W/%/&1M:2) M?_R/W[90,'LGS,2G22Y&B-)_8G];T:BN/EQ+*L(LD#+7 )=] MU1D@9&J@2L7>$HI[MV*T3>7T3*XYV[X.X=4C* M#"UYI[E>\GW(GP'9N07TN7FK[NT6<^;K?NGL@P1,).-RR0YZ[9LA@WME!29U MYMXWR5?2,YVS0B9Q?&\&!A-&"P$_F*[90QJ_1I[=36]EL_C:<#YS+(PSN9"\ M%E66]2#M\]W]09=#A8FI6?50#YZ^V@IQYJH5?R6ZFYJJ'4D^1CI'_']_C9WQ MJWME6D9#S0RA?]ENUJ6S MWP0X/S\R)$&I>2NNYF+^RE]!B3HCGQ:&5YO&=U .G*_+]AUCA2"G%?VFZE4[ MT:!-D8)NS!5]S?JF&)B1L2N2./DO4$L#!!0 ( 9(.E4:<26/3P, +D, M 1 ;'!C;BTR,#(R,#DR-BYX AR*B?-3Q;OOX2[][<>&AD^,/[Y'YM3]BC,XHL*B%3D6(+_A0 M'*$K,H86.@<.DF@AC] =88FUB#/*0**N&,<,-!A'&JF%#BI!@R",=]"] QX) M>7MSL=!]U#I6+=^?3J<5+B9D*N23JH1BO)M@7Q.=J(5:=5;-?KO1+ZD*%^1F MXS)6GV)_=?IP,R;@SF8B)^#:_4 M/&+=N%:[[8O3-&1;A8\P)L@M5X0<^;5J-? ?+GM]A_-28&O& M*'\J@@?-9M-WWARZA9P-),NEZ[YU#XB"A;+QTE?PE"M->+B&C_2"L H^\%/G M&I060ALIE.;0"#9P"L+*2$Q\XS#X6BT')@J/"(D7X"%1 R>JI,8JB1WXN9[# MC;40NJ9IJ7H>@RI6=:XU0N^Z>[7 ,AJ+D'*P7>E0U6:M86:+P1BX/A-R? I# MDC"3R'-"&!U2B#RDB1R!MFVF8A+"&VIYKQ+.A6EI,U>9Q=KBF)J>-89W;7NX M+2D8?#((6$A0DKQUFF4DC)#/DN+?9GM4<*PX[$XY#@_GI^FM(KIC!QBI5^9*+?SF[N1 M! M5&8J6F9:)HGE#I1+(N?MD<0+MW)1?/42W"Y<"^T:='$/9]?^+D$+.3XPK7++ M7Z6P]LB43^2YOBJ$4U/I7#8?N]WRR-\]DT,FL&]\4\+JJ_@7Y^%D2AW(6FM' M6OI6PHI6<37 M>#E=-YBNF^UUT"$(N%:SLL,Q2HE_]BO,Y?_9\KU07H(MA7V M#;M'%VP'+VJ!MI^JF>4?4$L#!!0 ( 9(.E4:! MF_0H ("& 5 M;'!C;BTR,#(R,#DR-E]L86(N>&ULS9U=;^.X%8;O"_0_L.Y-"XSCB8-=(-G) M+C*>9&%L-DECSVS;1;&@)<81(I,!)2?VOR\IB;)$\DA*BI*K\1&C/^]7Y>U_N8Y\_9V63R M^OIZ1-D+?F7\*3N*V&98A8L)XT>QL MER7G([G?:K>O)T>,KR?3CQ^/)__\]7H1/9(-'B=4'K>(C%24K,46=WQZ>CHI M2I744.Y6/%7[.)DH.W7-HC3IT#><9,E95MB[9A'.BV[OW0T"%?)_8R4;RTWC MX^GXY/AHE\4C=?"+(\A92N[) RJ:>9;OGP5*62))&%7;'CEYL)M).9_(^ DE M:YR36.[H5.[H^'NYH[]6FZ_QBJ0C))6"#[!=IZVZJJ"):[-WA"[(OOCL\_Q\:T(QWWH0ERW'Z+O/-2.>V;\C[CO@ASOV1%N,\>=^1;D3^7VSG MIN4W'U[[<4WEQFOQJ661['(Q@9%8F915=(S Q1Z*B:&JNZZ=1:UZ4SF:,VZV M7K+.'1>P" M,-J2<9*Q+8_(FWJEZ18Z2I6C32H4B1DL+VL6NNMEF2O5RLRR(3K88TOM829#4..[@"['C6.[\*L5KBWVM MW%476VVI/FX5!M')-D=Z+]<:)$6^NOD+R2*>/,OE?%<[6C+GG6XQ:?1]0Q,6 M J8QF(2&UM/ ?D_6B9Q:I 5Y?DODQHYA#-"['OH[;>MS@54.+J@=(O3>_+,>!<^;9EK:FPF=5B:FJ 8L1@#T2BUJ!1[(N(?6W'&3GBZ M[X7"4+KF K"JHZ')@J+#[@T$I);[963),PW<5/+0X6(=WA0(J*,"3C/)'4N W1PY"A=$T/8%7G1I,% M18S=&\A**4>%WC\DES0>A$BM\P.(9M..1R4*$(ZVLSXTA-HG&%=)%N&T]'(E MMF4=S;-H70,"VM4A,81!@0*Y V$I Q0S18A78/Y%,!^&2T/I!Q;#JAV56A8@ M*+JW/DRDW@LDLRWG+=?PC -+G=V4[3%;WY\%=$& TF/.N&M;REN@>)J!+FF> MY'OY/-W-=K,BW-(X4^**#>5W<):"X?8@2; MH\O<$F WV::@K0F(!*LQ@(:#MGBFU L1,S$R<9S.:4QVOY ]V"Y#YY8)P&8; M"DT4$!5V9P 6E1@5:B3D7L"XX\D&\_TBB7JF"E/H%@W(:)L-7140'( U@(Y* MC1;SF<^99(EW\UB FCPDY?/@/92 >K>P]-AN,P.( T*GVR% D A"[2B?(,UI MQ/@S:SSN,&-;,0#N9RR&5R@]46ZA&M2$-EJ=(0$!-L0G@%DK]$/Y3 IB\CV> MH@(D:_!"W$4Z!9OK) H#EY0U-/_$-S,A2:DZ"A.7D7-*+C MO8XU,_'QEB_9J^WA;%#I!1G3JA68@RP\7 QO?;#( +F>D2$^,2D65K?\CK.7 MA$;PDAF2>P$&,&VE1M.&AX[=8!\_]8)8Q7D=:\I%>>^71,G\C#)MD_8AIM2$ M!TG;6._@4JI](G''LARG_TZ>.T_$[6(O>%@-6R%I*<-#Q6:O#Y@R!HD@'R?6 M%:[RAH;U53*MW-TKP!9;AU> &X5!0&!S9+X"7%X]*46NNUDRR@D&1H1VL;-. MMIBJ^[A1%D87FX:,'BZ^UT+CXXLLL[ND=X^,P@\(F!)7/0V94[VMEP?1XX I MO=<+&2ITGJ[&RPP3F7WX;I0YF]EU._5$K@J"Z%W=C3%-JW+'O?D;3W*QYQG; M;+:TNLMC>VX0T+GJY4Z;JL>MHB!ZO\N93D*E16VQ8RP6+$VB)$_H^E=Q\LD3 M;&N53>0*"-B@HL%4!($":$OGX"!$2ND8@CM.)(1$=$3Q$J!,+,1O'QZLLWV7 MV!44_885'+ R"$AZ[>FPB(!QU(A 90@J8OQB,\^R+>%O@L<2X@DAT#P DJ$/ M$2?(9"]49:!/MA8DVHKY<7\\72V3/+6=7)H29W,28*Z>D;3R(-@ 3.DL%&6( M/:#CZ=]6?T;8O]7XH.EE8#.64[++IMU4DN;* A&NIP9:2W+I',-,9)JUUQLXR0G M<6GF*J&81@E.Z_2(MBOB_2'.:!EHO@:G1Q\&0\-,&CB582J781UX2'7I^E)Z M^0#&;R1-?Z'LE2X(SA@E<7DMQ7:GJ%OO]HF9'MOMAV8 <1 X#7$(/#HC@\9/ M,@JIL.I*F!>2OK%T2W/,BW?)N6UD G1NR0%LMHG11 &18G<&$%*+4:GV\X)V MF3VB7F25OSL$-A"2.WY=N].T]M:V51L0,YT&H7>XJYP?A[5Q&>7I%9@DE&3P1:2JW+%@M MMEEH20)BP>8+8*&0(J7UPL+EAO"UF-Y^YNPU?ZSRLX)M ]1NV>BTW&;$*@V( ME2Y_ #,J!)4Q*J6N'WAVAX3B999%N*46J6-L0+,:,X8N)& @ M,91!@-1K#_X=DCH"J1#'U-P*AGGS/*XP,<_)!GS;H3_$%4%#S2N.^O1!T#30 MI,Y4$=8^N2X"D8STF7N*U1(Y7QA:#VL*XH0B"$= 6M"QN_E: G]QY MVU6:1%V% [2;#!T1 :$WP"9TPZ&(1$7H M!U0&HT:TI_.S[) %D,2?]_?D@7#YWL&2[/+/8D=/'6<8 V)=G[T-;HY^,M<; M& 2$;W4+G>IEJ%D!6LEGQ*HJT.^R$E348OO]\N:F:_%);%:;Q%\KG!&QY;]0 M2P,$% @ !D@Z5=BZJR]6!P U5< !4 !L<&-N+3(P,C(P.3(V7W!R M92YX;6S-G%USXC84AN\[T__@TFL@D';;9)/N)&S883:[24-VM^W-CK %:")+ MC"0'^/>5;,SR8+=*>?1,E6927+9ZG9-61$4L M$R9FEZTOX_;5># :M2)MB$@(EX)>MH1LO?OKYY\B^W/Q2[L=#1GER7GT7L;M MD9C*M]%GDM+SZ ,55!$CU=OH*^&9VR*'C%,5#62ZX-10^T71\'GT>Z?WAD3M M-J#>KU0D4GUY&&WKG1NST.?=[G*Y[ CY3)92/>E.+%-8A6-#3*:WM9VL3C8_ M1?$+SL33N?LU(9I&EI?0YRO-+ENNW4VSR]..5+-N_^2DU_WGT^TXGM.4M)EP MW&+:*DNY6JK*]<[.SKKYMZ7T2+F:*%ZV<=HMN[.MV7[+ OJ=GFAVKO/NWN>R*P7=L?4S.U7K:B[ MU^Y"44V%R:W>V@U[1>C*V-V))F5%KGUHSPPS3KS967I1V^U966K;LA\+Y:8C M95>XC/=:YRX"\L!JN3?GG#6-.S/YW$THZSK[[D/.(6=@__F>-W0UT4:1V)0U M<3*A/*__N]4<2+H-]*HD\6AKK.[4ON*P3[M!NU)Q)%5"E65=UD54O!>JXQUS MH^@NB+(5M>,YX]LH3Y5,?70V)*2GH[N@;!/-T+RR[2>N#T-.9M4X#R1 GCT, MH)5NL(B^ISI6;.&XU(#=4P+Y]E'Y5GAK&'-Y[#S0&7/]=5UQIUOJ-H;'!4\1 M(/A3S)$BZ!8I E="9(0_T(54->#WE4#>OV'RKO*&A/GOC"A#%5]#2!^)@;!_ MQX3M<8C$^U$1H9GC P%^K 82?X-ZX>'QB(1\/*>7J4'8O\#$[O? MYRL ?_/LSN_VU )GOU,$B/_/UX+_R"U2!.ZI8C*QIW0%8'\D!E(_PZ3N<8C* M^T8D4-I;*3C_P8=]8 \)]9#IF/"B1T.[38=Q5\BAR%%RSEJ;J-C_I42!H>^( MH"O?\R['TX=I0\M-;F*\%^^C+LIW#L*+EHK4U, M[ /[\4X]RJ7G";17#$6.DHO66,0$GI]I[M2]DL^LF!-51_VH!!0]8HH:-HNZ MPQ7BJAO!'3U6ISF)SOI3:$_\<6=5>2U7HH<\3$-62TZ1N,1=S=30O? M5*(#"90O2JY:::=II"["BA+_[KNO@ )%24"KS#3,\U:Z9Q]S*8+W8X]54*XH MF:3/5-,#KYM(K+V'_L[7X!EL*,/JH8V&,7Y3S-@>#&2:9F)SC\;S5,PCA>)% M2?^"]AI&/9:=N?SN-Q* M W4WG?I&WI >2APEUZLWBDM^I'5&U4OY5Y2"1@$E[8.:;GJ./:B9'P^ M4TALB[GA]HBZFW V(_Z59,$"X'4VF,0#5IM>OY(8;-(\],,=7UFS_0],633PQ!_7PDH?\0' MBF&S://GU<">>&8R_,S\0 BEC3@5MM(:"N1Q2CB_SC035 ?'E@,A%#+BG-=* M:RB0;U*J9G90^Z#DTLPW:SM#L#T%H- 19[8&K>+ 7_U81UZL?PN2KU"#WTZ MB-UK$NNU&W'L)E(49W*1$.6A'M)#N:,NK/0;;9C\G9E3M7O]E'=F9/.VT*2' M^E+0**"DJU#3..?6G97\P5/KG@[*&S$QK3*&LV8JFW 6#[DDP>OR/1F4+V(6 M6F$+!>\U$4\J6YAX?:]D3*E[?**W1QL@(0)6 T)8G[Z(A0XMPMDFKK%1#)^ M&L^M:7V7F?SMI;9_P9L&P7+0T& NX@081[H*TC\6>M'D>OU IU2Y:0J/=&6N M;4-/X8LB0'%H?%#?* 3&4!&FB^Z1KUN[P;V?MOC&_7+O8+5;_@=02P$"% ,4 M " &2#I5V,VON.,/ !42@ "@ @ $ 97@Y.2TQ M+FAT;5!+ 0(4 Q0 ( 9(.E5=743O61( 'N. + " M 0L0 !F;W)M."UK+FAT;5!+ 0(4 Q0 ( 9(.E5/8[*!0A4 #<6 . M " 8TB !F;W)M."UK7S Q+FIP9U!+ 0(4 Q0 ( 9( M.E4:<26/3P, +D, 1 " ?LW !L<&-N+3(P,C(P.3(V M+GAS9%!+ 0(4 Q0 ( 9(.E4:! MF_0H ("& 5 " M 7D[ !L<&-N+3(P,C(P.3(V7VQA8BYX;6Q02P$"% ,4 " &2#I5V+JK M+U8' #55P %0 @ &I1@ ;'!C;BTR,#(R,#DR-E]P&UL4$L%!@ & 8 <@$ #). $! end